US2023295586A1PendingUtilityA1

Udp-glycosyltransferases

Assignee: DSM IP ASSETS BVPriority: Jun 27, 2017Filed: Mar 20, 2023Published: Sep 21, 2023
Est. expiryJun 27, 2037(~10.9 yrs left)· nominal 20-yr term from priority
C12Y 204/01C12N 9/1051A23V 2250/262C12P 19/56C12P 33/00A23K 20/163A23L 29/30A23L 27/36A23L 2/60A23V 2002/00C12N 9/0042
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates a polypeptide having UGT activity, which polypeptide comprises an amino acid sequence which, when aligned with a polypeptide having UGT activity comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 35, 189, 280, 284, 285, 334 or 373, said positions being defined with reference to SEQ ID NO: 2 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having UGT activity. A polypeptide according to the disclosure may be used in a recombinant cell for the production of steviol or a steviol glycoside.

Claims

exact text as granted — not AI-modified
1 . A polypeptide having UGT activity, which polypeptide comprises an amino acid sequence which, when aligned with a polypeptide having UGT activity comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions
 35, 189, 280, 284, 285, 334 or 373   said positions being defined with reference to SEQ ID NO: 2 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having UGT activity.   
     
     
         2 . A polypeptide according to  claim 1 , wherein the modified property is modified UGT activity. 
     
     
         3 . A polypeptide according to  claim 1 , wherein the UGT activity is UGT3 activity. 
     
     
         4 . A polypeptide according to  claim 1 , wherein the reference polypeptide comprises the UGT of SEQ ID NO: 2. 
     
     
         5 . A polypeptide according to  claim 1 , wherein:
 (i) a valine is present at position 35;   (ii) a alanine is present at position 189;   (iii) an asparagine is present at position 280;   (iv) an asparagine is present at position 284;   (v) a glycine is present at position 285   (vi) an asparagine is present at position 285   (vii) a serine is present at position 285   (viii) an alanine is present at position 334; and/or   (ix) an alanine is present at position 373.   said positions being defined with reference to SEQ ID NO: 2.   
     
     
         6 . A polypeptide according to  claim 1 , comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity with SEQ ID NO: 2. 
     
     
         7 . A polypeptide having UGT activity comprising an amino acid sequence having at least about 95% sequence identity, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18 or 20.

Join the waitlist — get patent alerts

Track US2023295586A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.